← back to search

Sasan Roayaie

White Plains Hospital · US
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, and Cholangiocarcinoma and Gallbladder Cancer Studies.
h-index
53
citations
25,899
works
179
NIH funding
primary concept
email

Recent publications

Targeting TIGIT to improve outcomes in advanced HCC
JHEP Reports 2025cited by 0position: contributordoi
Author Correction: Hepatocellular carcinoma
Nature Reviews Disease Primers 2024cited by 40position: middledoi
Hepatocellular carcinoma
Nature Reviews Disease Primers 2021cited by 6,342position: middledoi
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Journal of Hepatology 2020cited by 285position: middledoi
Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
Journal of Hepatology 2018cited by 543position: middledoi
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Gut 2018cited by 333position: middledoi
Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma
Annals of Surgery 2018cited by 219position: middledoi
Frontline Science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS
Journal of Leukocyte Biology 2016cited by 48position: middledoi
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Oncology 2015cited by 1,098position: middledoi
The role of hepatic resection in the treatment of hepatocellular cancer
Hepatology 2015cited by 410position: firstdoi
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Nature Communications 2015cited by 296position: middledoi
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Gastroenterology 2013cited by 586position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Josep M. Llovet · Mayo Clinic in Florida5 papers (2013–2024)Vincenzo Mazzaferro · Fondazione IRCCS Istituto Nazionale dei Tumori5 papers (2013–2018)Myron Schwartz · Mount Sinai Health System3 papers (2013–2015)Masatoshi Kudo · Kindai University3 papers (2015–2018)Philip J. Johnson · University of Liverpool3 papers (2015–2018)Augusto Villanueva · NYU Langone Health3 papers (2013–2024)Eli Pikarsky · Hadassah Medical Center2 papers (2021–2024)Yujin Hoshida · WinnMed2 papers (2013–2015)Amit G. Singal · Stanford University2 papers (2021–2024)Robin Kate Kelley · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2021–2024)Daniela Sia · Dana-Farber Cancer Institute2 papers (2013–2015)Helena Cornellà · Lund University2 papers (2013–2015)Alessandro Cucchetti · Azienda-Unita' Sanitaria Locale Di Cesena2 papers (2018–2018)Kazuhiko Koike · Kanto Central Hospital2 papers (2021–2024)Riccardo Lencioni · University of Pisa2 papers (2021–2024)Jessica Zucman‐Rossi · Inserm2 papers (2021–2024)Richard S. Finn · United States Olympic & Paralympic Committee2 papers (2021–2024)Josep Fuster · Hospital Clínic de Barcelona2 papers (2013–2015)Jordi Bruix · Instituto de Salud Carlos III2 papers (2013–2015)Swan N. Thung · Mount Sinai Health System2 papers (2013–2015)